Louis Plamondon

Louis Plamondon serves as the Executive Vice President and Head of Chemistry, Manufacturing, and Controls (CMC) at LifeMine Therapeutics. He earned his Ph.D. in Organic Chemistry from the Université de Montréal, where he studied under James D. Wuest. Following his doctoral studies, he completed a postdoctoral fellowship at Harvard University under the guidance of Stuart L. Schreiber. Before joining LifeMine Therapeutics, Plamondon was the Senior Vice President and Head of CMC at Constellation Pharmaceuticals, a MorphoSys company. He is a co-inventor and leader for Velcade® (bortezomib), the first proteasome inhibitor approved for treating multiple myeloma, and a co-inventor for Xerava® (Eravacycline), the first fully synthetic fluorocycline used for treating complicated intra-abdominal infections (cIAI).